GlassScriptPhysician profile
Megan Elmore
NPI 1144997313
$652.49
in general payments reported to CMS, 2019-2025
11 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4.05 · 2022: $67.11 · 2023: $141 · 2024: $13.08 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.33 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $160.53 | 2025 | Tremfya |
| Lilly USA, LLC | $156.44 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $102.79 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $75.52 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $45.60 | 2022-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $38.80 | 2025 | Entyvio |
| Ardelyx, INC. | $22.55 | 2025 | Ibsrela |
| Genzyme Corporation | $21.31 | 2025 | |
| Aimmune Therapeutics, INC. | $15.15 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $9.75 | 2025 | Voquezna |
| Genentech USA, INC. | $4.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Elmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.